Finanzen von Benitec Biopharma Inc (BNTC)BNTCBenitec Biopharma Inc

Benitec Biopharma Inc (BNTC) generates its revenue primarily from Licensing revenue, which accounts for 100.0% of total sales, equivalent to $2.00K. Understanding this concentration is critical for investors evaluating how BNTC navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Benitec Biopharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -29.58%, provide a clear picture of how effectively BNTC converts its operational activities into shareholder value.

In the context of the broader market, BNTC competes directly with industry leaders such as FENC and RCKT. With a market capitalization of $428.40M, it holds a significant position in the sector. When comparing efficiency, BNTC's gross margin of N/A stands against FENC's 95.97% and RCKT's N/A. Such benchmarking helps identify whether Benitec Biopharma Inc is trading at a premium or discount relative to its financial performance.

Benitec has shown a consistent trend of net losses, with Q3 2026 reporting a net loss of $11.9 million and an EPS of -0.24, although it beat expectations by $0.04, indicating some operational improvement.